Charles Schwab’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-457,772
| Closed | -$23.6M | – | 3607 |
|
|
2022
Q3 | $23.6M | Buy |
457,772
+75,528
| +20% | +$3.12M | 0.01% | 1259 |
|
|
2022
Q2 | $9.47M | Buy |
382,244
+14,545
| +4% | +$321K | ﹤0.01% | 1864 |
|
|
2022
Q1 | $9.22M | Buy |
367,699
+8,653
| +2% | +$243K | ﹤0.01% | 2001 |
|
|
2021
Q4 | $13.1M | Buy |
359,046
+32,613
| +10% | +$1.14M | ﹤0.01% | 1861 |
|
|
2021
Q3 | $5.58M | Sell |
326,433
-26,705
| -8% | -$416K | ﹤0.01% | 2322 |
|
|
2021
Q2 | $4.73M | Sell |
353,138
-21,530
| -6% | -$530K | ﹤0.01% | 2382 |
|
|
2021
Q1 | $19.2M | Buy |
374,668
+9,064
| +2% | +$545K | 0.01% | 1566 |
|
|
2020
Q4 | $22.6M | Buy |
365,604
+1,650
| +0.5% | +$94.5K | 0.01% | 1309 |
|
|
2020
Q3 | $19.9M | Buy |
363,954
+250,259
| +220% | +$13.5M | 0.01% | 1205 |
|
|
2020
Q2 | $6.54M | Buy |
113,695
+10,612
| +10% | +$578K | ﹤0.01% | 1898 |
|
|
2020
Q1 | $4.14M | Buy |
103,083
+2,773
| +3% | +$118K | ﹤0.01% | 1925 |
|
|
2019
Q4 | $3.97M | Buy |
100,310
+3,616
| +4% | +$63.5K | ﹤0.01% | 2144 |
|
|
2019
Q3 | $656K | Sell |
96,694
-45,868
| -32% | -$344K | ﹤0.01% | 2700 |
|
|
2019
Q2 | $1.33M | Buy |
142,562
+93,385
| +190% | +$1.08M | ﹤0.01% | 2487 |
|
|
2019
Q1 | $684K | Hold |
49,177
| – | – | ﹤0.01% | 2657 |
|
|
2018
Q4 | $537K | Hold |
49,177
| – | – | ﹤0.01% | 2739 |
|
|
2018
Q3 | $622K | Hold |
49,177
| – | – | ﹤0.01% | 2768 |
|
|
2018
Q2 | $648K | Buy |
49,177
+6,077
| +14% | +$72.7K | ﹤0.01% | 2711 |
|
|
2018
Q1 | $587K | Buy |
43,100
+7,900
| +22% | +$81.5K | ﹤0.01% | 2693 |
|
|
2017
Q4 | $210K | Hold |
35,200
| – | – | ﹤0.01% | 2977 |
|
|
2017
Q3 | $262K | Sell |
35,200
-22,600
| -39% | -$188K | ﹤0.01% | 2927 |
|
|
2017
Q2 | $542K | Buy |
57,800
+25,800
| +81% | +$189K | ﹤0.01% | 2663 |
|
|
2017
Q1 | $233K | Hold |
32,000
| – | – | ﹤0.01% | 2906 |
|
|
2016
Q4 | $237K | Hold |
32,000
| – | – | ﹤0.01% | 2925 |
|
|
2016
Q3 | $194K | Hold |
32,000
| – | – | ﹤0.01% | 2926 |
|
|
2016
Q2 | $144K | Sell |
32,000
-3,000
| -9% | -$11.3K | ﹤0.01% | 3015 |
|
|
2016
Q1 | $88K | Hold |
35,000
| – | – | ﹤0.01% | 2997 |
|
|
2015
Q4 | $284K | Hold |
35,000
| – | – | ﹤0.01% | 2880 |
|
|
2015
Q3 | $212K | Hold |
35,000
| – | – | ﹤0.01% | 2943 |
|
|
2015
Q2 | $289K | Hold |
35,000
| – | – | ﹤0.01% | 2892 |
|
|
2015
Q1 | $265K | Hold |
35,000
| – | – | ﹤0.01% | 2881 |
|
|
2014
Q4 | $240K | Hold |
35,000
| – | – | ﹤0.01% | 2928 |
|
|
2014
Q3 | $158K | Sell |
35,000
-16,339
| -32% | -$86.4K | ﹤0.01% | 3002 |
|
|
2014
Q2 | $301K | Sell |
51,339
-336
| -0.7% | -$1.89K | ﹤0.01% | 2859 |
|
|
2014
Q1 | $343K | Buy |
51,675
+1,260
| +2% | +$8.76K | ﹤0.01% | 2748 |
|
|
2013
Q4 | $292K | Buy |
50,415
+1,512
| +3% | +$7.8K | ﹤0.01% | 2821 |
|
|
2013
Q3 | $268K | Buy |
48,903
+2,037
| +4% | +$22K | ﹤0.01% | 2803 |
|
|
2013
Q2 | $671K | Buy |
+46,866
| New | +$607K | ﹤0.01% | 2369 |
|
Other funds holding CCXI
Charles Schwab's CCXI Position: Q4 2022 in Review
Charles Schwab sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 457,772 shares — an estimated $23.6M sold.
Charles Schwab first reported a position in CCXI in Q2 2013 and held it in 38 quarters. The position peaked at $23.6M in Q3 2022. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- Charles Schwab reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- Charles Schwab sold 457,772 ChemoCentryx, Inc. shares in Q4 2022, an estimated $23.6M.
- Charles Schwab first reported a position in ChemoCentryx, Inc. in Q2 2013 and held it in 38 quarters.
- Charles Schwab's ChemoCentryx, Inc. position peaked at $23.6M in Q3 2022.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on Charles Schwab's 13F filing for Q4 2022, filed 13 Feb 2023.